Substrate Characterization and Outcomes of Ventricular Tachycardia Ablation in Amyloid Cardiomyopathy: A Multicenter Study
Circulation: Arrhythmia and Electrophysiology · 2024-09 · 17 (9)
DOI: 10.1161/circep.124.012788 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Circulation: Arrhythmia and Electrophysiology, 2024-09. Verfasst von Paolo Compagnucci und 17 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology and Arrhythmology Clinic, University Hospital Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy (P.C., A.D.R., M.C.). Hauptthemen laut MEDLINE: Tachycardia, Ventricular, Catheter Ablation, Cardiomyopathies, Recurrence. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Sustained ventricular tachycardia (VT) in cardiac amyloidosis is uncommon, and the substrate and outcomes of catheter ablation are not defined. METHODS: We included 22 consecutive patients (mean age, 68±10 years; male sex, 91%) with cardiac amyloidosis (ATTR [transthyretin], n=16; light chain, n=6) undergoing catheter ablation for VT/ventricular fibrillation (VF) between 2013 and 2023 in a retrospective, observational, international study. The primary efficacy outcome was recurrent VT/VF during follow-up, while the primary safety end point included major procedure-related adverse events. RESULTS: The indication for ablation was drug-refractory VT in 17 patients (77%), and premature ventricular complex–initiated polymorphic VT/VF in 5 patients (23%). Catheter ablation was performed using endocardial (n=17.77%) or endo-epicardial approaches (n=5.23%). Complete endocardial electroanatomical voltage maps of the left and right ventricles were obtained in 17 (77%) and 10 (45%) patients, respectively. Each patient had evidence of low-voltage areas, most commonly involving the interventricular septum (n=16); late potentials were recorded in 16 patients (73%). A median of 1 (1–2) VT was inducible per patient; 12 of the 26 mappable VTs (46%) originated from the interventricular septum. Complete procedural success was achieved in 16 patients (73%), with 4 (18%) major procedure-related adverse events. After a median follow-up of 32 (14–42) months, sustained VT/VF recurrence was observed in 9 patients (41%); survival free from VT/VF recurrence was 56% (95% CI, 36%–86%) at 36-month follow-up, and most patients remained on antiarrhythmic drugs. A significant reduction in per patient implantable cardioverter defibrillator therapies was noted in the 6-month period after ablation (before: 6 [4–9] versus after: 0 [0–0]; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiology and Arrhythmology Clinic, University Hospital Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy (P.C., A.D.R., M.C.).
- Department of Biomedical Sciences and Public Health (A.D.R., A.G.), Marche Polytechnic University, Ancona, Italy.
- Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD (A.G.).
- Department of Clinical Electrophysiology and Cardiac Pacing, Centro Cardiologico Monzino, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy (M.S., C.T.).
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (O.S., S.K., K.C.S.).
- Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN (K.H., W.G.S., H.T.).
ORCID-Profile: Paolo Compagnucci, Alessio Gasperetti, Marco Schiavone, Ojasav Sehrawat, Kanae Hasegawa, Sanghamitra Mohanty, Jackson J Liang, Suraj Kapa, Vincenzo Mirco La Fazia, William G Stevenson, Claudio Tondo, Konstantinos C Siontis, Pasquale Santangeli, Andrea Natale, Michela Casella
Zitieren
APA
Compagnucci, P., Dello Russo, A., Gasperetti, A., Schiavone, M., Sehrawat, O., Hasegawa, K., Mohanty, S., Liang, J. J., Kapa, S., La Fazia, V. M., Bogun, F., Stevenson, W. G., Tondo, C., Siontis, K. C., Tandri, H., Santangeli, P., Natale, A., & Casella, M. (2024). Substrate Characterization and Outcomes of Ventricular Tachycardia Ablation in Amyloid Cardiomyopathy: A Multicenter Study. Circulation: Arrhythmia and Electrophysiology, 17(9). https://doi.org/10.1161/circep.124.012788
Vancouver
Compagnucci P, Dello Russo A, Gasperetti A, Schiavone M, Sehrawat O, Hasegawa K, et al. Substrate Characterization and Outcomes of Ventricular Tachycardia Ablation in Amyloid Cardiomyopathy: A Multicenter Study. Circulation: Arrhythmia and Electrophysiology. 2024;17(9). doi:10.1161/circep.124.012788
BibTeX
@article{Compagnucci2024,
author = {Compagnucci, Paolo and Dello Russo, Antonio and Gasperetti, Alessio and Schiavone, Marco and Sehrawat, Ojasav and Hasegawa, Kanae and Mohanty, Sanghamitra and Liang, Jackson J and Kapa, Suraj and La Fazia, Vincenzo Mirco and Bogun, Frank and Stevenson, William G and Tondo, Claudio and Siontis, Konstantinos C and Tandri, Harikrishna and Santangeli, Pasquale and Natale, Andrea and Casella, Michela},
title = {Substrate Characterization and Outcomes of Ventricular Tachycardia Ablation in Amyloid Cardiomyopathy: A Multicenter Study},
journal = {Circulation: Arrhythmia and Electrophysiology},
year = {2024},
volume = {17},
number = {9},
doi = {10.1161/circep.124.012788}
}
EUVIMED